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In the etiology of Behc¸et’s disease (BD), viral infection has long been postulated as a
contributing factor, and viral involvement has been demonstrated. However, viral infection
alone is not sufficient to explain the pathogenesis of BD, and some evidence suggests that
immunologic abnormalities are also important. To study the possible role of immune regu-
lation in the development of BD-like symptoms induced by herpes simplex virus inoculation
in ICR mice, macrophages were deleted by use of liposome-encapsulated clodronate (lip-
Cl2MDP). Treatment with lip-Cl2MDP suppressed the development of BD-like symptoms,
and this suppression was correlated with the induction of interleukin-4 expression in mouse
spleens. When the Th2 adjuvant ovalbumin (OVA)–alum was injected into mice with BD-like
symptoms, their cutaneous symptoms improved. Adoptive transfer with splenocytes from
OVA-alum–injected mice also resulted in improvement. These findings suggest that up-regu-
lated Th2 cytokine expression can attenuate the development of and improve some BD-like
symptoms.
Behc¸et’s disease (BD) is a chronic multisystemic disorder with
mucocutaneous, ocular, arthritic, vascular, gastrointestinal, and
central nervous system involvement. The etiology of BD has
been linked to viral infection, autoimmune disease, streptococ-
cal-related antigens, specific alleles of the human major histo-
compatibility complex, and hazardous chemicals [1–4]. Since
Huluˆsi Behc¸et first propounded viral etiology in 1937 [5], many
studies have suggested a viral involvement in the disease. Sezer
[6] isolated a specific virus from patient fluids, and Eglin and
Lehner [7] showed herpes simplex virus (HSV) type 1 gene
fragments in peripheral blood mononuclear cells of patients
with BD by means of in situ DNA-RNA hybridization [7]. By
use of DNA-DNA dot blotting and polymerase chain reaction
(PCR) analysis, HSV DNA also was detected in leukocytes and
saliva from patients with BD [8, 9].
Treatment with acyclovir, which is of proven efficacy in the
treatment of HSV infection, did not much alleviate the frequency
or severity of orogenital ulceration or other clinical features of
BD [10]. Lymphocyte dysfunction has been reported by several
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research groups. When stimulated by small doses of staphylo-
coccal enterotoxins (superantigen), T lymphocytes from patients
with BD had a distinctly lower threshold for interferon (IFN)–g
production than lymphocytes from patients with rheumatoid ar-
thritis or from healthy control subjects [11]. The mucocutaneous
lesions of BD were initially infiltrated with CD4 and CD8 cells,
macrophages and dendritic cells, followed by neutrophils. Recent
attention has focused on Th1 and Th2 cytokines. Persons with
active BD have significantly more interleukin (IL)–2–producing
CD4 cells than do inactive case subjects and control subjects [12],
and IL-12 plasma level and disease activity are correlated [13].
These results suggest that Th1 cells may play an important role
in the immunopathogenesis of BD, although others have reported
that the cytokine production profile has a mixed Th1/Th2 cell
type in active BD [14]. In this study, we attempted to determine
whether inactivation of macrophages influences the development
of BD and whether related cytokines play a role in the modu-
lation of BD symptoms.
Materials and Methods
Animals and induction of BD symptoms. We used 4–5-week-
old male ICR mice (Korean Laboratory Animal Research Center)
for this study. By using the method of Hirata et al. [15], we
scratched the earlobes of the mice with a needle and then inoculated
them with 106 pfu/mL of HSV-1 (F strain). Virus inoculation was
done 2 times 10 days apart, which was followed by 16 weeks of
observation [16]. Mice were bred in temperature- and light-con-
trolled conventional rooms (20C–22C; 12-h light cycle starting at
8:00 A.M.). The mice had free access to food and water. During
the experimental period, the animals were closely observed and
were photographed.
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Figure 1. Behc¸et’s disease–like symptoms (oral, genital, and skin:
a–c, respectively) in herpes simplex virus–induced ICR mice.
Table 1. ICR mice manifesting symptoms of Behc¸et’s
disease (BD) after herpes simplex virus (HSV) inocu-
lation and/or immune cell inactivation.
Treatment
Mice with BD
symptoms Dead mice
Lip-Cl2MDP 0/50 0/50
Lip-Cl2MDP  HSV 0/50 9/50 (18.0)
HSV 14/50 (28.0) 10/50 (20.0)
NOTE. Data are no. of mice/total no. of mice (%). Lip-
Cl2MDP, liposome-encapsulated clodronate.
Figure 2. Immunohistochemistry of macrophage-inactivated mice.
Spleen tissues of liposome-encapsulated chlodronate–injected mice
rarely were stained with anti-mac2 antibody (b), unlike those of PBS-
injected mice (a). Figure is 1 of 5 replicate samples from 2 representative
experiments.
Gross observation of BD symptoms. To classify the sympto-
matic mice as having BD, we followed a revised Japanese classi-
fication with minor modifications. Oral, genital, and other skin
ulcers (including bulla and crust) and eye symptoms were classified
as major symptoms. Arthritis, gastrointestinal ulcers, and neuro-
logic involvement were identified as minor symptoms. Mice with
1 major and 1 minor symptom were classified as having BD.
Symptomatic mice were photographed with a Nikon FM2 camera
equipped with a 105-mm microlens.
Liposome-encapsulated chlodronate (Lip-Cl2MDP) preparation.
Lip-Cl2MDP was prepared, as described elsewhere [17]. In brief,
75 mg of phosphatidyl choline and 11 mg of cholesterol (Sigma)
were dissolved in chloroform in a round-bottom flask. After low-
vacuum rotary evaporation at 37C, the lipids were dispersed by
gentle rotation in 10 mL of PBS, in which 2.5 g of dichloro-
methylene diphosphonate (Cl2MDP; Boehringer Mannheim) was
dissolved. The resulting liposomes were washed 2 times at
for 30 min, to remove free nonencapsulated Cl2MDP.100,000 g
The liposomes then were resuspended in 4 mL of PBS. Lip-Cl2MDP
was injected intravenously in mice to inactivate their macrophages.
Mice were treated intravenously with 200 mL of lip-Cl2MDP 2 days
before HSV infection.
Antibody preparation. We cultured a hybridoma cell line as fol-
lows: ATCC TIB-166 (M3/38.1.2.8 HL2), an anti-mac2 antibody-
producing cell line, was cultured in RPMI 1640 medium with 20%
fetal bovine serum (FBS). At the time of cell lysis, the supernatant
was collected and concentrated (Centriplus-50; Amicon). We mea-
sured the concentration of antibody by using a protein assay kit (Bio-
Rad). Concentrated antibodies were used for immunohistochemistry.
Immunohistochemistry. Mouse spleen tissues were embedded in
paraffin blocks and were used for histochemistry. Primary antibody
(anti-mac2) was produced in our laboratory by using American Type
Culture Collection hybridoma cell lines (anti-mac2 antibody, ATCC
TIB-166, and M3/38.1.2.8 HL2), since none were commercially avail-
able. We used horseradish peroxidase–conjugated rabbit anti–rat im-
munoglobulin as secondary antibody.
RNA isolation and reverse transcriptase (RT)–PCR. Total
RNA was isolated by acid guanidium thiocyanate–phenol-chloro-
form extraction [18]. Spleen tissues were homogenized in 1 mL of
extraction buffer (4 M guanidine solution [Aldrich], 25 mM sodium
citrate [pH 7.0], 0.5% sodium N-lauroyl sarcosinate [Fisher], and
0.1 M 2-mercaptoethanol [Sigma]). We added a 1:10 volume of
chloroform:isoamyl alcohol (49:1) to the samples, which were in-
cubated on ice for 5 min and were centrifuged at for10,000 g
15 min at 4C. RNA in the upper aqueous phase was collected,
was precipitated with an equal volume of isopropanol, and was
washed 2 times in 70% ETOH. RNA pellets were dissolved in
distilled water, were quantified at an OD of 260:280 determination,
and were visualized in an ethidium bromide–stained agarose gel.
We reverse-transcribed 2 mg of RNA with a cDNA kit (Gibco BRL)
by using oligo dT primers and avian myeloblastosis virus RT to
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Figure 3. Left, Expression of cytokines by reverse transcription–polymerase chain reaction analysis and flow cytometry (FACS) in spleens of
mice with Behc¸et’s disease (BD). Groups were injected with liposome-encapsulated chlodronate (lip-Cl2MDP; a), lip-Cl2MDP and herpes simplex
virus (HSV; b), and HSV (c). d, Normal healthy mice. Data for each group are mean of 3 mice from 2 representative experiments. Right, For
FACS analysis, 107 splenocytes from each group were cultured with Brefeldin A for 5 h and were stained with phycoerythrin- or fluorescein
isothiocyanate–labeled anti–mouse IgG. Photographs show 1 of 3 replicate samples from 2 representative experiments. Time schedules of inoc-
ulation: a, lip-Cl2MDP (day 0)rlip-Cl2MDP (day 10)rdeath (day 21). b, lip-Cl2MDP (day 0)rHSV (day 2)rlip-Cl2MDP (day 10)rHSV (day
12)rdeath (day 21). c, HSV (day 0)rHSV (day 10)rdeath (day 21). d, Virus culture media (day 0)rculture media (day 10)rdeath (day 21). IFN,
interferon; IL, interleukin.
generate cDNA for use as a template in PCR amplifications. Then
we added 2 mL from the RT reaction to 50-mL reaction mixtures
containing 50 mM KCl (pH 8.4), 20 mM Tris-HCl, 2.5 mM MgCl2,
200 mM dNTPs, 2.5 U of Taq polymerase (Gibco BRL), and 1.2
mM primers. Specific primers for cytokines and b-actin were as
follows: b-actin [19]; sense, 5′-TGGAATCCTGTGGCATCCATG-
AAAC-3′, and antisense, 5′-TAAAACGCAGCTCAGTAACAG-
TCCG-3′; IL-2 [20], sense, 5′-TGATGGACCTACAGGAGCTCC-
TGAG-3′, and antisense, 5′-GAGTCAAATCCAGAACATGCC-
GCAG-3′; IL-4 [21], sense, 5′-ACGCCATGCACGGAGATGGAT
-3′, and antisense, 5′-CAAGCATGGAGTTTTCC-3′; IL-10 [22];
sense, 5′-AGACTTTCTTTCAAACAAAGGACCAGCTGGA-3′,
and antisense, 5′-CCTGGAGTCCAGCAGACTCAATACACA-
CTGC-3′; IFN-g [19]; sense, 5′-AGCGGCTGACTGAACTCA-
GATTGTAG-3′, and antisense, 5′-GTCACAGTTTTCAGCTGT-
ATAGGG-3′.
The amplification was processed in a thermal cycler (model 900;
Perkin Elmer) with an initial 5-min denaturation at 94C, followed
by 35 cycles of the profile: 94C for 30 s, 56C for 30 s, and 72C
for 1 min. The products were subjected to electrophoresis on a
1.8% agarose gel and were visualized under UV light.
Flow cytometric analysis of intracellular cytokines. Before intra-
cellular cytokine staining, splenocytes were freshly isolated. Brefeldin
A (5 g/mL; Sigma) was added for the last 4 h of incubation, to
accumulate cytokines in the Golgi complex. Cells were harvested,
were washed in culture medium containing brefeldin A, and were
fixed with 4% formaldehyde in 1% FBS containing PBS for 20 min
at room temperature. Then cells were permeabilized with 0.1% sapo-
nin in PBS containing 1% FBS and 0.1% sodium azide (saponin
buffer) for 10 min at room temperature. Cell suspensions then were
treated with fluorescein isothiocyanate– or phycoerythrin-conjugated
anti–IL-4, IFN-g antibody (CalTag) suspended in permeabilized buf-
 at Y
O
N
SEI U
N
IV
ERSITY
 M
ED
ICA
L LIBRA
RY
 on A
ugust 6, 2014
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
JID 2001;183 (15 April) Role of Th2 Cytokine in Behc¸et’s Disease 1183
Figure 4. Reverse transcription–polymerase chain reaction (RT-
PCR) analysis of splenocyte cultures from ovalbumin (OVA)–alum– or
OVA–complete Freund’s adjuvant (CFA)–injected mice. Aseptically
isolated splenocytes from OVA-alum– or OVA-CFA–injected mice were
cultured for 2 days in Dulbecco’s MEM with 0.15 mg/mL of OVA.
Collected splenocytes underwent RT-PCR analysis. Splenocytes were
cultured from OVA-alum– or OVA-CFA–injected mice (left and right
lanes, respectively). IFN, interferon; IL, interleukin.
fer. Samples were analyzed by means of flow cytometer (FACS Van-
tage; Becton Dickinson) with 20,000 gated lymphocytes.
Induction of Th2 cytokine. Immunization consisted of 2 mg of
ovalbumin (OVA) adsorbed onto 2 mg of Al(OH)3 adjuvant given
by intraperitoneal injection on day 0. Spleens were removed 7 days
later, and splenocyte suspensions were cultured for 2 days with or
without 0.15-mg/mL OVA in Dulbecco’s MEM. For the control
experiment, OVA and complete Freund’s adjuvant (CFA) were in-
jected instead of OVA-alum. OVA-CFA (2 mg of OVA and 100 mL
of CFA) was mixed through a double-hubbed emulsifying needle
before injection. Cytokine production was assessed by RT-PCR
analysis, to determine whether alum could induce Th2 cytokines.
Mice that developed symptoms of BD were injected with OVA,
either in alum or emulsified in CFA. Treatment occurred on day
0 and on day 14 after BD symptoms developed.
Adoptive transfer. Splenocytes ( ) isolated from the65 10
spleens of mice treated with OVA in alum or emulsified in CFA
were transferred intravenously to mice exhibiting symptoms of BD.
Mice were observed for 7 days.
Results
Macrophage inactivation could decrease the incidence of BD-
like symptoms. To determine whether macrophages play a role
in the development of HSV-induced BD-like symptoms, ICR
mice were treated with lip-Cl2MDP to inactivate macrophages.
Symptoms appeared in the inoculated animals. As reported else-
where [9], these symptoms included bulla and crust in the face
region, erythema on the scratched earlobe, eye symptoms (e.g.,
hypopyon, iridoretinitis, retinal degeneration, and uveitis), and
skin ulcerations of the earlobes, scruff, genitalia, and other
regions (figure 1). Of interest, 14 (28%) of 50 HSV-inoculated
mice without lip-Cl2MDP treatment developed BD-like symp-
toms; however, no mice treated with lip-Cl2MDP before HSV
inoculation had BD-like symptoms. The control group, mice
treated with lip-Cl2MDP alone, did not exhibit any BD-like
symptoms. Mortality was similar between the HSV-inoculated
mice with and without lip-Cl2MDP (18% vs. 20%; table 1).
Spleen macrophages are nearly depleted by Lip-Cl2MDP treat-
ment (as shown by staining with anti-mac2 antibody). To permit
in vivo studies of macrophage function and immunologic process,
Van Rooijen [17] developed a lip-Cl2MDP–mediatedmacrophage
suicide technique. Lip-Cl2MDP–engulfed macrophages were
killed by apoptosis after phospholipase-mediated disruption of
the liposomal bilayers and release of the Cl2MDP [17]. To confirm
that the treatment with lip-Cl2MDP depletes the macrophages of
ICR mice, their spleens were immunohistochemically analyzed.
Lip-Cl2MDP was intravenously injected 2 times 10 days apart
in ICR mice. The spleen tissues of lip-Cl2MDP–injected mice
rarely were stained with anti-mac2 antibody (figure 2B), unlike
those of PBS-injected mice (figure 2A).
Lip-Cl2MDP treatment up-regulated IL-4 expression at
mRNA and protein levels. To address the possible role of
cytokines affected by macrophage knockout in the development
of BD-like symptoms, we used RT-PCR analysis to analyze the
mRNA expression of cytokines in the spleens of mice treated
with lip-Cl2MDP, lip-Cl2MD and HSV, or HSV alone. In all 3
experimental groups, IL-2 and IFN-g were expressed. However
IL-4 mRNA was expressed only in the spleens of mice treated
with lip-Cl2MDP or lip-Cl2MDP combined with HSV (figure
3, top).
To confirm the protein expression of intracellular cytokines,
we analyzed the expression of IL-4 and IFN-g by means of
flow cytometry. We found that IL-4 expression in splenocytes
was significantly up-regulated in mice treated with lip-Cl2MDP
or lip-Cl2MDP combined with HSV, compared with that in
HSV-inoculated mice (figure 3, bottom). IFN-g expression was
increased slightly in mice inoculated with HSV alone.
Th2 adjuvant and alum hydroxide mixed with OVA induced Th2
cytokines with accompanying improvement of skin symptoms.
To determine whether the Th2 adjuvant could systemically induce
Th2 cytokines (e.g., IL-4 and IL-10), especially in the spleen,
OVA-alum was injected into normal mice. In splenocytes cultured
from the OVA-alum–injected group, Th2 cytokine IL-4 and IL-
10 and Th1 cytokine IFN-g mRNA expression were demon-
strated by RT-PCR analysis. In the OVA-CFA–injected group,
only IFN-g was expressed (figure 4). To test whether Th2 cy-
tokines could attenuate the BD-like symptoms, mice with BD-
like symptoms were injected with OVA-alum. Improvement was
noted in 6 of 9 mice (figure 5). The symptoms that improved the
most were cutaneous problems, such as skin ulcers and crust on
the face, earlobes, scruff, and back (table 2). The remaining 3
mice had unchanged symptoms (e.g., ocular and neurologic in-
volvement). In OVA-FCA–injected BD-like mice, none of 6 an-
imals showed any improvement.
Symptom improvement after transfer of splenocytes from OVA-
alum–injected mice to BD-like mice. Adoptive transfer with
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Figure 5. Photographs of mice before (a) and after (b) ovalbumin
(OVA)–alum injection. OVA-alum was injected intraperitoneally 2
times 2 weeks apart into mice with Behc¸et’s disease with skin ulcerations
on their backs.
Table 2. Symptoms of mice with Behc¸et’s disease (BD)
and response to ovalbumin (OVA)–alum treatment.
Mouse, symptom(s)
Improvement
observed
1
Skin ulcer Yes
Arthritis No
2
Facial skin crust and periocular crust Yes
Earlobe edema Yes
3
Facial skin crust and ulcer Yes
Genital inflammation Yes
4
Skin ulcer Yes
Eye involvement Yes
5
Skin ulcer Yes
6
Earlobe edema Yes
Facial skin crust and ulcer Yes
7
Earlobe edema Yes
Skin ulcer Yes
8
Eye involvement No
9
Skin ulcer Yes
Neural involvement No
NOTE. OVA-alum was injected 2 times intraperitoneally at 2-
week intervals after BD symptoms occurred. BD symptoms im-
proved in 6 of 9 mice after OVA-alum immunization. None of 6
mice injected with OVA–complete Freund’s adjuvant had any
improvement.
splenocytes from OVA-alum–treated mice also resulted in the
improvement of BD-like symptoms (e.g., cutaneous ulcers of
the face, earlobe, and scruff and genital inflammation). In the
control experiment, splenocytes isolated from OVA-FCA–
treated mice were transferred to BD-like mice. These resulted
in the deterioration of skin ulcers of the BD-like mice or gen-
eration of other symptoms, such as ocular and cutaneous in-
volvement (figure 6).
Discussion
There is a hypothesis about the relationship between the
pathophysiology of BD and the autoimmune responses seen in
the disease. Antigens, such as bacteria, virus, and heat-shock
proteins, stimulate macrophages, and stimulated macrophages
activate T cells and neutrophils or induce tissue damage directly
[23]. Therefore, to determine whether elimination of macro-
phages can affect the development of BD-like symptoms, we
used lip-Cl2MDP to inactivate macrophages in a mouse model.
Animals treated with HSV combined with lip-Cl2MDP had a
lower incidence of BD-like symptoms than did those treated
with HSV alone. These results suggest that macrophages may
play an important role in the development of this disease.
Macrophage deletion did not seem to affect mortality in the 2
groups: HSV infection might be macrophage independent,
whereas the development of BD-like symptoms requires macro-
phage activity. The primary defense after HSV infection is me-
diated predominantly by polymorphonuclear cells rather than
by macrophages, which therefore resulted in fewer BD-like
symptoms. From this, we suggest that the incidence of BD
differs, depending on macrophage depletion, but that mortality
after HSV infection does not [24].
A possible polarization of T lymphocytes toward the Th1
type in BD has been suggested in experimental uveoretinitis
and in humans [25]. Plasma levels of IL-12, tumor necrosis
factor receptor–75, and soluble IL-2 receptor correlate with
disease activity in BD [26, 27]. Activated macrophages induce
cellular immunity by activating Th1 cell responses and by sup-
pressing Th2 cell responses [28]. IFN-g represents the key cyto-
kine produced by Th1 cells. IFN-g is a potent immunoregu-
latory factor that plays an important role in the activation of
macrophages by regulating antigen presentation. Antigen-pre-
senting cells exposed to virus secrete the Th1 cytokine, IFN-g.
IL-2 may contribute to the host defense by inducing the clonal
expansion of cytokine-producing T cells and by augmenting the
production of IFN-g [29].
As shown in figure 4, inoculation with HSV alone induced
IL-2 and IFN-g expression. Lip-Cl2MDP treatment also in-
duced IFN-g but to a lesser extent. IL-4 expression was seen
only in the lip-Cl2MDP–treated groups. IL-4 drives the differ-
entiation of naive CD4-positive cells in a Th2 direction [30].
Up-regulated IL-4 mRNA levels could be influential in de-
creasing the onset of recurrent BD-like ulceration in response
to HSV by altering the Th1/Th2 balance in the direction of
Th2 cells.
Macrophages induce cellular immunity by activating Th1 cell
responses and by suppressing Th2 responses [31], and macro-
phage depletion in mice shifts the Th1 response to a Th2 re-
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Figure 6. Transfer of splenocytes from ovalbumin (OVA)–alum–
treated mice attenuates symptoms of mice with Behc¸et’s disease (BD).
Aseptically isolated splenocytes from OVA-alum– or OVA–65 10
complete Freund’s adjuvant (CFA)–injected mice were transferred in-
travenously into mice with BD. Injection was OVA (2 mg) mixed in 2
mg of alum hydroxide or emulsified in 100 mL of CFA. OVA-alum or
OVA-CFA was injected 2 times 2 weeks apart. Two days after the final
injection, mice were killed, and splenocytes were isolated. micenp 5
per group.
sponse [32]. Our studies also show that HSV inoculation in-
duces the expression of Th1 cytokines alone, whereas
lip-Cl2MDP or lip-Cl2MDP combined with HSV treatment in-
duces the expressions of both Th1 and Th2 cytokines. Thus,
lip-Cl2MDP knocks out macrophages that regulate the expres-
sion of cytokines secreted by macrophages. The degree of
macrophage inactivation is correlated with the incidence of BD-
like symptoms. In HSV-inoculated mice with macrophages in-
activated by anti-mac1 antibody, 20% developed BD-like symp-
toms versus 10% of mice with macrophages inactivated by
anti-mac1 and anti-mac2 antibodies [33]. IL-4 mRNA, even
with weak expression, could help the improvement of symptoms
in ICR mice. Thus, Th2 cytokine expression might be critical
in inhibiting BD-like symptoms induced by HSV.
The use of CFA as an adjuvant in immunocompetent mice
produces a predominantly Th1 type response, whereas alum pro-
duces a polarized Th2 type response [34]. The effect of alum is
due to the suppression of Th1 development via an IL-4–depen-
dent mechanism [35]. Six of 9 BD-like mice improved when in-
jected with OVA-alum, although 4 regressed 2–3 weeks after the
initial improvement. The 3 mice that did not improve had ocular
and neurologic symptoms. In clinical experience, the pathogen-
esis of BD can be divided into several subtypes by the type of
disease expression. For example, ocular symptoms reflect more
humoral immunity balance, whereas mucocutaneous symptoms
are related to cell-mediated immunity. Bang [36] suggested that
therapeutic plans are divided into 2 categories by humoral or
cell-mediated immunity involvement. Another possible expla-
nation could come from experiments with the Lewis rat. Many
researchers induced recurrent autoimmune uveitis similar to oc-
ular symptoms of BD in the Lewis rat but no other BD symptoms
(e.g., orogenital ulcerations) [37]. We assume that the different
responses to OVA-alum treatment can be explained with different
pathogenic mechanisms between orogenital and skin involvement
and ocular and neural involvement.
In conclusion, we demonstrated that macrophage inactiva-
tion decreases the incidence of HSV-induced BD in mice. This
result was associated with the induction of IL-4 expression.
Both Th2 adjuvant treatment and adoptive transfer could at-
tenuate some of the disease symptoms. Therefore, Th2 cytokine
expression induced by macrophage inactivation may be closely
related to the development, deterioration, and improvement of
BD induced by HSV.
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